These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 21664905)

  • 21. Clinical utilization of atypical antipsychotics in pregnancy and lactation.
    Gentile S
    Ann Pharmacother; 2004; 38(7-8):1265-71. PubMed ID: 15150376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
    McIntyre RS; Jerrell JM
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Schizophrenia and comorbid metabolic disorders.
    Henderson DC
    J Clin Psychiatry; 2005; 66 Suppl 6():11-20. PubMed ID: 16107179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study.
    van Winkel R; Moons T; Peerbooms O; Rutten B; Peuskens J; Claes S; van Os J; De Hert M
    Int Clin Psychopharmacol; 2010 Sep; 25(5):270-6. PubMed ID: 20523222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abnormal glucose metabolism in patients treated with antipsychotics.
    Scheen AJ; De Hert MA
    Diabetes Metab; 2007 Jun; 33(3):169-75. PubMed ID: 17412628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
    Rzewuska M
    Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic risk during antipsychotic treatment.
    Newcomer JW
    Clin Ther; 2004 Dec; 26(12):1936-46. PubMed ID: 15823759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism.
    Terry AV; Mahadik SP
    J Pharmacol Exp Ther; 2007 Mar; 320(3):961-8. PubMed ID: 16966470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapeutic options for weight management in schizophrenic patients treated with atypical antipsychotics].
    Cordes J; Sinha-Röder A; Kahl KG; Malevani J; Thuenker J; Lange-Asschenfeldt C; Hauner H; Agelink MW; Klimke A
    Fortschr Neurol Psychiatr; 2008 Dec; 76(12):703-14. PubMed ID: 18924059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications.
    Buckley PF; Miller DD; Singer B; Arena J; Stirewalt EM
    Schizophr Res; 2005 Nov; 79(2-3):281-8. PubMed ID: 15964743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring for metabolic complications associated with atypical antipsychotics.
    Farver D
    S D J Med; 2005 Feb; 58(2):53-4. PubMed ID: 15756776
    [No Abstract]   [Full Text] [Related]  

  • 32. [Metabolic disorders in patients with schizophrenia treated with atypical antipsychotic drugs].
    Gorobets LN; Bulanov VS; Vasilenko LM; Litvinov AV; Poliakovskaia TP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(9):90-6. PubMed ID: 23373080
    [No Abstract]   [Full Text] [Related]  

  • 33. Aripiprazole and pregnancy: A retrospective, multicentre study.
    Galbally M; Frayne J; Watson SJ; Snellen M
    J Affect Disord; 2018 Oct; 238():593-596. PubMed ID: 29957476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Both physical activity and food intake are associated with metabolic risks in patients with schizophrenia.
    Wang J; Fan X; Liu D; Yi Z; Freudenreich O; Goff D; Henderson DC
    Schizophr Res; 2012 Sep; 140(1-3):260-1. PubMed ID: 22682987
    [No Abstract]   [Full Text] [Related]  

  • 35. Management of schizophrenia in women during the perinatal period: a synthesis of international recommendations.
    Lefebvre A; Pouchon A; Bioulac S; Mallet J; Polosan M; Dondé C
    Expert Opin Pharmacother; 2022 Aug; 23(11):1337-1350. PubMed ID: 35835161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Metabolic disorders under antipsychotic treatment].
    Steffenhagen N; Rummel-Kluge C; Himmerich H
    Nervenarzt; 2012 Mar; 83(3):337-44. PubMed ID: 21206997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Societal Valorisation of New Knowledge to Improve Perinatal Health: Time to Act.
    Steegers EA; Barker ME; Steegers-Theunissen RP; Williams MA
    Paediatr Perinat Epidemiol; 2016 Mar; 30(2):201-4. PubMed ID: 26860446
    [No Abstract]   [Full Text] [Related]  

  • 38. Significance of metabolic disorders in schizophrenia.
    Rowntree DW
    Lancet; 1973 Jul; 2(7821):151. PubMed ID: 4124071
    [No Abstract]   [Full Text] [Related]  

  • 39. Vitamin D and the perinatal period in women suffering from schizophrenia.
    Jankovic J; McDonald L; Johnston-Webber C
    Ment Health Fam Med; 2012 Dec; 9(4):215-7. PubMed ID: 24294295
    [No Abstract]   [Full Text] [Related]  

  • 40. Could maternal perinatal atypical antipsychotic treatments program later metabolic diseases in the offspring?
    Guillemot J; Laborie C; Dutriez-Casteloot I; Maron M; Deloof S; Lesage J; Breton C; Vieau D
    Eur J Pharmacol; 2011 Sep; 667(1-3):13-6. PubMed ID: 21664905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.